Get the Stockscreener App
0.9094
3.96%
0.022
Verrica Pharmaceuticals Inc stock is traded at $0.9094, with a volume of 689.90K.
It is up +3.96% in the last 24 hours and down -41.24% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$0.8874
Open:
$0.896
24h Volume:
689.90K
Relative Volume:
0.75
Market Cap:
$41.40M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-1.722
EPS:
-0.5281
Net Cash Flow:
$-38.94M
1W Performance:
+6.86%
1M Performance:
-41.24%
6M Performance:
-89.48%
1Y Performance:
-75.00%
1-Day Range:
$0.85
$1.024
1-Week Range:
$0.7919
$1.024
52-Week Range:
$0.7043
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| VRCA | 0.9169 | 41.40M | 5.12M | -67.00M | -38.94M | -0.5281 |
| VRTX | 447.28 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.63 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.30 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.57 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.98 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Announces Pricing of $42.0 Million Public Offering - GlobeNewswire
Verrica Pharmaceuticals Raises $42M Through Public Offering of Shares and Warrants | VRCA Stock News - StockTitan
Form 424B5 Verrica Pharmaceuticals - StreetInsider.com
Verrica Pharmaceuticals announces proposed public offering - MSN
Verrica Announces Proposed Public Offering - The Manila Times
Verrica Pharmaceuticals Announces Public Offering of Stock and Warrants with Jefferies | VRCA Stock News - StockTitan
Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock - Investing.com
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock By Investing.com - Investing.com UK
Q1 Earnings Forecast for VRCA Issued By HC Wainwright - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to “Neutral” at HC Wainwright - Defense World
Verrica downgraded to sector perform by RBC Capital - MSN
Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Verrica Pharmaceuticals Announces Leadership Transition and Financial Results for Q3 2024 - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to "Neutral" at HC Wainwright - MarketBeat
RBC Capital Downgrades Verrica Pharmaceuticals (VRCA) - MSN
Verrica Pharmaceuticals Reports Q3 2024 EPS of -$0.49 and Revenue of -$1.9 Million, Misses Estimates - GuruFocus.com
Verrica Pharmaceuticals stock hits 52-week low at $0.93 - Investing.com
U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn
Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com South Africa
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Sector Perform Rating by Royal Bank of Canada - MarketBeat
Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com
Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian
Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring - TipRanks
Botanix Pharmaceuticals Poised for Market Impact with Sofdra Launch - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat
Verrica shares price target cut by TD Cowen - Investing.com Canada
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire
GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Verrica Pharmaceuticals reports board changes, non-compliance - Investing.com India
Verrica Pharmaceuticals reports board changes, non-compliance By Investing.com - Investing.com Australia
Recent Insider Activity Could Benefit Verrica Pharmaceuticals Inc (VRCA) - Knox Daily
Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks
Optinose Names Terry Kohler as CFO - MarketWatch
Optinose names Terry Kohler as new CFO By Investing.com - Investing.com UK
Optinose Appoints Terry Kohler as Chief Financial Officer - Marketscreener.com
The Significance of Moving Averages in Verrica Pharmaceuticals Inc Inc. (VRCA) Price Performance - The InvestChronicle
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):